Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Cohen

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
British Journal of Haematology|June 6, 2024
Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib-based regimeJoshua Bomsztyk, Sriram Ravichandran, Jahanzaib Khwaja, et al.
Haematologica|January 11, 2024
Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patientsJahanzaib Khwaja, Sriram Ravichandran, Joshua Bomsztyk, et al.
European Journal of Haematology|January 18, 2021
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UKFaye A Sharpley, Richa Manwani, Aviva Petrie, et al.
Blood Cancer Journal|August 18, 2022
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research GroupAndrea Havasi, Cihan Heybeli, Nelson Leung, et al.
Blood|January 9, 2024
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosisJoshua Bomsztyk, Sriram Ravichandran, Hannah V Giles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2022
Graded Cardiac Response Criteria for Patients With Systemic Light Chain AmyloidosisEli Muchtar, Angela Dispenzieri, Brendan Wisniowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2025
New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging SystemJahanzaib Khwaja, Amy A Kirkwood, Paolo Milani, et al.
JAMA Oncology|August 1, 2024
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain AmyloidosisEli Muchtar, Brendan Wisniowski, Susan Geyer, et al.
JAMA Cardiology|August 21, 2024
Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL AmyloidosisAldostefano Porcari, Ambra Masi, Ana Martinez-Naharro, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
British Journal of Haematology|June 6, 2024
Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib-based regimeJoshua Bomsztyk, Sriram Ravichandran, Jahanzaib Khwaja, et al.
Haematologica|January 11, 2024
Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patientsJahanzaib Khwaja, Sriram Ravichandran, Joshua Bomsztyk, et al.
European Journal of Haematology|January 18, 2021
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UKFaye A Sharpley, Richa Manwani, Aviva Petrie, et al.
Blood Cancer Journal|August 18, 2022
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research GroupAndrea Havasi, Cihan Heybeli, Nelson Leung, et al.
Blood|January 9, 2024
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosisJoshua Bomsztyk, Sriram Ravichandran, Hannah V Giles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2022
Graded Cardiac Response Criteria for Patients With Systemic Light Chain AmyloidosisEli Muchtar, Angela Dispenzieri, Brendan Wisniowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2025
New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging SystemJahanzaib Khwaja, Amy A Kirkwood, Paolo Milani, et al.
JAMA Oncology|August 1, 2024
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain AmyloidosisEli Muchtar, Brendan Wisniowski, Susan Geyer, et al.
JAMA Cardiology|August 21, 2024
Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL AmyloidosisAldostefano Porcari, Ambra Masi, Ana Martinez-Naharro, et al.
Pageof 2